abrdn Life Sciences Investors (NYSE:HQL) Shares Down 2.3% – Should You Sell?

abrdn Life Sciences Investors (NYSE:HQL) shares were down 2.3% during trading on Tuesday . The company traded as low as $17.05 and last traded at $17.19. 146,167 shares were traded during trading, an increase of 46% from the average daily volume of 99,899 shares. The stock had previously closed at $17.60.

abrdn Life Sciences Investors Price Performance

The business’s 50-day simple moving average is $17.36 and its 200-day simple moving average is $17.06.

abrdn Life Sciences Investors Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Thursday, May 21st will be issued a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a dividend yield of 13.0%. The ex-dividend date is Thursday, May 21st.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. raised its position in abrdn Life Sciences Investors by 200.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after acquiring an additional 1,529 shares in the last quarter. Global Retirement Partners LLC increased its stake in shares of abrdn Life Sciences Investors by 187.8% during the 4th quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after purchasing an additional 4,593 shares during the last quarter. Cornerstone Advisors LLC acquired a new position in shares of abrdn Life Sciences Investors during the 3rd quarter worth $175,000. Mercer Global Advisors Inc. ADV bought a new position in shares of abrdn Life Sciences Investors during the 4th quarter valued at $177,000. Finally, Evolve Private Wealth LLC bought a new position in shares of abrdn Life Sciences Investors during the 4th quarter valued at $199,000. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.